• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 3. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 4. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 5. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425

Professional Introduction to Compound with CAS No. 1443286-07-4 and Product Name: 8-Bromopyrido[2,3-bpyrazine]

The compound with the CAS number 1443286-07-4 is a specialized chemical entity that has garnered significant attention in the field of pharmaceutical research and development. Its product name, 8-Bromopyrido[2,3-bpyrazine, highlights its structural characteristics as a brominated derivative of a pyridopyrazine scaffold. This compound represents a fascinating class of heterocyclic molecules that have been extensively explored for their potential biological activities and applications in medicinal chemistry.

Pyridopyrazine derivatives are known for their diverse pharmacological properties, making them valuable scaffolds in the design of novel therapeutic agents. The introduction of a bromine atom at the 8-position, as seen in 8-Bromopyrido[2,3-bpyrazine, enhances its reactivity and functionalization potential, which is crucial for further chemical modifications and derivatization. These modifications are often essential for optimizing drug-like properties such as solubility, bioavailability, and target specificity.

Recent advancements in the field of medicinal chemistry have demonstrated the importance of 8-Bromopyrido[2,3-bpyrazine] in the development of small-molecule inhibitors targeting various disease pathways. For instance, studies have shown that this compound exhibits promising activity against enzymes involved in cancer progression. The brominated pyridopyrazine core serves as an effective handle for covalent bond formation with biological targets, leading to potent and selective inhibition.

In addition to its applications in oncology, 8-Bromopyrido[2,3-bpyrazine] has been investigated for its potential in treating inflammatory and neurodegenerative diseases. The unique structural features of this compound allow it to interact with specific binding sites on disease-related proteins, modulating their activity and alleviating symptoms. Researchers have leveraged computational modeling and high-throughput screening techniques to identify derivatives of 8-Bromopyrido[2,3-bpyrazine] that exhibit enhanced pharmacological profiles.

The synthesis of 8-Bromopyrido[2,3-bpyrazine] involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions, have been employed to construct the pyridopyrazine core efficiently. These synthetic strategies not only improve the accessibility of the compound but also enable the introduction of various functional groups for further medicinal chemistry exploration.

One of the key advantages of using 8-Bromopyrido[2,3-bpyrazine] as a building block is its versatility in generating structurally diverse libraries of compounds. By employing combinatorial chemistry approaches, researchers can rapidly generate and screen large collections of derivatives to identify lead compounds with desired biological activities. This approach has been instrumental in accelerating drug discovery pipelines and bringing novel therapeutics to market faster.

The pharmacokinetic properties of 8-Bromopyrido[2,3-bpyrazine] are also an area of active investigation. Understanding how this compound is absorbed, distributed, metabolized, and excreted (ADME) is crucial for optimizing its therapeutic potential. Preclinical studies have provided valuable insights into its pharmacokinetic behavior, guiding efforts to improve its bioavailability and reduce toxicity. These studies often involve sophisticated analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy to characterize the compound's metabolic pathways.

Future directions in the research of 8-Bromopyrido[2,3-bpyrazine] include exploring its role in emerging therapeutic areas such as precision medicine and immunotherapy. The ability to tailor its structure for specific biological targets makes it a promising candidate for personalized treatment strategies. Additionally, advancements in drug delivery systems may enhance the efficacy of 8-Bromopyrido[2,3-bpyrazine]-based therapies by improving their targeted delivery to diseased tissues.

In conclusion,8-Bromopyrido[2,3-bpyrazine (CAS No. 1443286-07-4) is a versatile and highly functionalized heterocyclic compound with significant potential in pharmaceutical applications. Its unique structural features and reactivity make it an invaluable tool for drug discovery researchers seeking to develop novel therapeutics against various diseases. As our understanding of molecular interactions continues to evolve,8-Bromopyrido[2,3-bpyrazine] will undoubtedly play a crucial role in shaping the future of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)